A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Principal investigator: Juha Lievonen
HUS, Helsinki University Hospital, Comprehensive Cancer Center

Link to the Orphanet Clinical Trials register